Literature DB >> 10389687

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options.

H N Nguyen1, B Backes, F Lammert, J Wildberger, R Winograd, N Busch, H Rieband, S Matern.   

Abstract

This report describes two patients with pancreatic cholera caused by vasoactive intestinal polypeptide (VIP)-producing tumors, which originated in the pancreas and showed metastases in both hepatic lobes at time of diagnosis. However, the two tumors displayed remarkably disparate clinical courses. Due to the protracted but progressive course over more than 10 years, a multifaceted therapeutic approach was performed to control symptoms and to improve quality of life. The long-acting somatostatin analog octreotide was the most effective treatment for relieving symptoms and correcting fluid and electrolytes disturbances. The effects of complementary treatments, including systemic chemotherapy and hyperselective chemoembolization, as well as concurrent application of octreotide and prednisolone or interferon with respect to clinical symptoms, VIP levels, and tumor growth are reviewed. Our experience, although small, emphasizes the need for an expert, well-planned, adaptive, and multidisciplinary approach in the care of these complex patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389687     DOI: 10.1023/a:1026672022917

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology.

Authors:  R P Rood; R A DeLellis; Y Dayal; M Donowitz
Journal:  Gastroenterology       Date:  1988-03       Impact factor: 22.682

2.  Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas.

Authors:  L Makowka; A G Tzakis; V Mazzaferro; L Teperman; A J Demetris; S Iwatsuki; T E Starzl
Journal:  Surg Gynecol Obstet       Date:  1989-02

Review 3.  Endocrine pancreatic carcinoma.

Authors:  M Rothmund; B Stinner; R Arnold
Journal:  Eur J Surg Oncol       Date:  1991-04       Impact factor: 4.424

Review 4.  Metastatic carcinoid tumors and the malignant carcinoid syndrome.

Authors:  L K Kvols; J C Reubi
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

5.  An update of the medical treatment of malignant endocrine pancreatic tumors.

Authors:  B Eriksson; K Oberg
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

Review 6.  Pancreatic vipomas: spectrum of presentation and evolution of diagnostic and therapeutic modalities.

Authors:  S F Leavey; H Holloway; M G Courtney; B E Lane; D Royston; K D Buchanan; J F Fielding
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

7.  Somatostatin analogue therapy in functioning neuroendocrine gut tumors.

Authors:  H T Debas; G Gittes
Journal:  Digestion       Date:  1993       Impact factor: 3.216

8.  Chromogranin A(210-301) is the major form of pancreastatin-like material in human gut extracts and endocrine tumors.

Authors:  M C Woussen-Colle; P Lingier; P Vertongen; M C Vandermeers-Piret; A Vandermeers; P Robberecht
Journal:  Peptides       Date:  1994       Impact factor: 3.750

9.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

10.  Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma.

Authors:  A Koelz; M Kraenzlin; K Gyr; V Meier; S R Bloom; P Heitz; H Stalder
Journal:  Gastroenterology       Date:  1987-02       Impact factor: 22.682

View more
  7 in total

1.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  Vasoactive intestinal peptide secreting tumour: An overview.

Authors:  Esther Una Cidon
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

Review 3.  Pancreatic VIPomas: subject review and one institutional experience.

Authors:  Amir A Ghaferi; Karen A Chojnacki; William D Long; John L Cameron; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

Review 4.  Multimodal Treatment of Vasoactive Intestinal Polypeptide-producing Pancreatic Neuroendocrine Tumors with Liver Metastases.

Authors:  Mari Iwasaki; Kouhei Tsuchida; Hidehito Jinnai; Toshinori Komatsubara; Takahiro Arisaka; Misako Tsunemi; Masakazu Nakano; Makoto Iijima; Hideyuki Hiraishi
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

5.  Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature.

Authors:  Xiao Hu; Wei Cao; Min Zhao
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

Review 6.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

7.  Surgical resection of vasoactive intestinal peptideoma with hepatic metastasis aids symptom palliation: A case report.

Authors:  Xiaomei Zhang; Lingli Zhou; Ying Liu; Wei Li; Hongkai Gao; Yunan Wang; Baoting Yao; Daming Jiang; Peijun Hu
Journal:  Exp Ther Med       Date:  2016-01-22       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.